Zoe K McQuilten1, Vijaya Sundararajan2, Nick Andrianopoulos1, David J Curtis3, Erica M Wood1,3, Lynda J Campbell2,4, Meaghan Wall4. 1. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. 2. Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, Australia. 3. Australian Centre for Blood Diseases, Monash University, Melbourne, Australia. 4. Victorian Cancer Cytogenetics Service, St Vincent's Hospital, Melbourne, Australia.
Abstract
BACKGROUND: Conflicting data exist about the impact of a monosomal karyotype (MK) on overall survival (OS) for patients with myelodysplastic syndromes (MDSs) and particularly for those with a complex karyotype (CK). This study was aimed at determining whether an MK is associated with OS independently of the number of cytogenetic abnormalities (CAs) in a population-based MDS cohort. METHODS: Cancer registry data on incident MDS cases were linked with cytogenetic data and hospital administrative data from 2000 to 2010 for the Australian state of Victoria. RESULTS: Between 2000 and 2010, 1404 incident MDS cases with cytogenetic results were identified. A CK, defined as 3 or more abnormalities, was present in 126 (9%). A very complex karyotype (vCK), defined as 5 or more abnormalities, was present in 95 (7%). An MK was associated with worse OS in the whole cohort (median 6 vs 39 months, P < 0.001) including those with a coexisting CK (6 vs 17 months, P < 0.001) or vCK (6 vs 9 months, P = 0.02). After adjustments for the number of CAs, an MK remained independently associated with OS, although its effect size decreased with increasing cytogenetic complexity (hazard ratio for an MK, 4.81; 95% confidence interval, 3.08-7.52; hazard ratio for the number of CAs, 1.22; 95% confidence interval, 1.15-1.30; and hazard ratio for the interaction between an MK and CAs, 0.83; 95% confidence interval, 0.77-0.89). CONCLUSIONS: These results support the clinical utility of an MK as an independent predictor of adverse outcomes for MDS patients, even among CK and vCK groups, although its prognostic effect decreases with increasing cytogenetic complexity.
BACKGROUND: Conflicting data exist about the impact of a monosomal karyotype (MK) on overall survival (OS) for patients with myelodysplastic syndromes (MDSs) and particularly for those with a complex karyotype (CK). This study was aimed at determining whether an MK is associated with OS independently of the number of cytogenetic abnormalities (CAs) in a population-based MDS cohort. METHODS: Cancer registry data on incident MDS cases were linked with cytogenetic data and hospital administrative data from 2000 to 2010 for the Australian state of Victoria. RESULTS: Between 2000 and 2010, 1404 incident MDS cases with cytogenetic results were identified. A CK, defined as 3 or more abnormalities, was present in 126 (9%). A very complex karyotype (vCK), defined as 5 or more abnormalities, was present in 95 (7%). An MK was associated with worse OS in the whole cohort (median 6 vs 39 months, P < 0.001) including those with a coexisting CK (6 vs 17 months, P < 0.001) or vCK (6 vs 9 months, P = 0.02). After adjustments for the number of CAs, an MK remained independently associated with OS, although its effect size decreased with increasing cytogenetic complexity (hazard ratio for an MK, 4.81; 95% confidence interval, 3.08-7.52; hazard ratio for the number of CAs, 1.22; 95% confidence interval, 1.15-1.30; and hazard ratio for the interaction between an MK and CAs, 0.83; 95% confidence interval, 0.77-0.89). CONCLUSIONS: These results support the clinical utility of an MK as an independent predictor of adverse outcomes for MDSpatients, even among CK and vCK groups, although its prognostic effect decreases with increasing cytogenetic complexity.
Authors: M Rasche; C von Neuhoff; M Dworzak; J-P Bourquin; J Bradtke; G Göhring; G Escherich; G Fleischhack; N Graf; B Gruhn; O A Haas; T Klingebiel; B Kremens; T Lehrnbecher; A von Stackelberg; J Tchinda; Z Zemanova; C Thiede; N von Neuhoff; M Zimmermann; U Creutzig; D Reinhardt Journal: Leukemia Date: 2017-04-25 Impact factor: 11.528
Authors: Detlef Haase; Kristen E Stevenson; Donna Neuberg; Jaroslaw P Maciejewski; Aziz Nazha; Mikkael A Sekeres; Benjamin L Ebert; Guillermo Garcia-Manero; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Seishi Ogawa; Yasunobu Nagata; Kenichi Yoshida; Timothy A Graubert; Matthew J Walter; Alan F List; Rami S Komrokji; Eric Padron; David Sallman; Elli Papaemmanuil; Peter J Campbell; Michael R Savona; Adam Seegmiller; Lionel Adès; Pierre Fenaux; Lee-Yung Shih; David Bowen; Michael J Groves; Sudhir Tauro; Michaela Fontenay; Olivier Kosmider; Michal Bar-Natan; David Steensma; Richard Stone; Michael Heuser; Felicitas Thol; Mario Cazzola; Luca Malcovati; Aly Karsan; Christina Ganster; Eva Hellström-Lindberg; Jacqueline Boultwood; Andrea Pellagatti; Valeria Santini; Lynn Quek; Paresh Vyas; Heinz Tüchler; Peter L Greenberg; Rafael Bejar Journal: Leukemia Date: 2019-01-11 Impact factor: 12.883
Authors: Eve Roman; Alex Smith; Simon Appleton; Simon Crouch; Richard Kelly; Sally Kinsey; Catherine Cargo; Russell Patmore Journal: Cancer Epidemiol Date: 2016-04-16 Impact factor: 2.984